1. Academic Validation
  2. Biological activities of fusarochromanone: a potent anti-cancer agent

Biological activities of fusarochromanone: a potent anti-cancer agent

  • BMC Res Notes. 2014 Sep 3;7:601. doi: 10.1186/1756-0500-7-601.
Elahe Mahdavian 1 Phillip Palyok Steven Adelmund Tara Williams-Hart Brian D Furmanski Yoon-Jee Kim Ying Gu Mansoureh Barzegar Yang Wu Kaustubh N Bhinge Gopi K Kolluru Quincy Quick Yong-Yu Liu Christopher G Kevil Brian A Salvatore Shile Huang John L Clifford
Affiliations

Affiliation

  • 1 Department of Chemistry and Physics, LSU-Shreveport, One University Place, Shreveport, LA 71115, USA. emahdavi@lsus.edu.
Abstract

Background: Fusarochromanone (FC101) is a small molecule Fungal metabolite with a host of interesting biological functions, including very potent anti-angiogenic and direct anti-cancer activity.

Results: Herein, we report that FC101 exhibits very potent in-vitro growth inhibitory effects (IC50 ranging from 10nM-2.5 μM) against HaCat (pre-malignant skin), P9-WT (malignant skin), MCF-7 (low malignant breast), MDA-231 (malignant breast), SV-HUC (premalignant bladder), UM-UC14 (malignant bladder), and PC3 (malignant prostate) in a time-course and dose-dependent manner, with the UM-UC14 cells being the most sensitive. FC101 induces Apoptosis and an increase in proportion of cells in the sub-G1 phase in both HaCat and P9-WT cell lines as evidenced by cell cycle profile analysis. In a mouse xenograft SCC tumor model, FC101 was well tolerated, non-toxic, and achieved a 30% reduction in tumor size at a dose of 8 mg/kg/day. FC101 is also a potent anti-angiogenenic agent. At nanomolar doses, FC101 inhibits the vascular endothelial growth factor-A (VEGF-A)-mediated proliferation of endothelial cells.

Conclusions: Our data presented here indicates that FC101 is an excellent lead candidate for a small molecule anti-cancer agent that simultaneously affects angiogenesis signaling, Cancer signal transduction, and Apoptosis. Further understanding of the underlying FC101's molecular mechanism may lead to the design of novel targeted and selective therapeutics, both of which are pursued targets in Cancer drug discovery.

Figures
Products